QTTB: Promising phase II results for an IL-7/TSLP biologic in AA set the stage for pivotal trials
The session highlighted a promising IL-7/TSLP-targeting biologic for alopecia areata, with strong phase II results and a large addressable market. Phase III will leverage lessons from earlier trials, with robust enrollment and maintenance dosing data planned. Cash runway supports pivotal developmen…